DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Could sacituzumab govitecan be the new standard in treating endocrine refractory metastatic hormone receptor-positive breast cancer?
Delve into the latest findings from the TROPiCS-02 study, a phase three trial in patients with metastatic hormone receptor-positive breast cancer, presented by Dr. Sara Tolaney at ASCO 2023.
Key Points:
- The TROPiCS-02 study is a phase three trial involving patients with metastatic hormone receptor-positive breast cancer.
- Patients were randomized to receive either sacituzumab govitecan or a treatment of the physician’s choice.
- The study showed a consistent improvement in progression-free survival from about four months to 5.5 months.
- Overall survival improved significantly, going from 11.2 months to 14.5 months.
Additional Points:
- The patient population had progressed on prior endocrine therapy and had received prior taxane.
- Patients could have received 2 to 4 prior lines of chemotherapy in the metastatic setting.
Conclusion:
- The TROPiCS-02 study suggests that sacituzumab govitecan offers a significant survival benefit for patients with endocrine refractory metastatic hormone receptor-positive breast cancer, positioning it as a new standard treatment option.
Radiation Oncology Latest Posts
- Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations
- mRNA Vaccination Linked to Long-Term Survival for Patients with Solid Tumors
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
- Yale Study Finds Reduced Opioid Prescribing for Some Patients with Cancer
Did You Know?
According to the American Cancer Society, hormone receptor-positive breast cancer is the most common type of breast cancer, accounting for about 2 out of 3 cases.
